Journal
VACCINE
Volume 26, Issue 22, Pages 2762-2771Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.03.009
Keywords
West Nile virus; single-cycle virus; subviral particles
Categories
Funding
- NIAID NIH HHS [R21AI77077, U54AI057156] Funding Source: Medline
Ask authors/readers for more resources
Safer vaccines are needed to prevent flavivirus diseases. To help develop these products we have produced a pseudoinfectious West Nile virus (WNV) lacking a functional C gene which we have named RepliVAX WN. Here we demonstrate that RepliVAX WN can be safety propagated at high titer in BHK cells and vaccine-certified Vero cells engineered to stably express the C protein needed to trans-complement RepliVAX WN growth. Using these BHK cells we selected a better growing mutant RepliVAX WN population and used this to generate a second-generation RepliVAX WN (RepliVAX WN.2). RepliVAX WN.2 grown in these C-expressing cell tines safety elicit strong protective immunity against WNV disease in mice and hamsters. Taken together, these results indicate the clinical utility of RepliVAX WN.2 as a vaccine candidate against West Nile encephalitis. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available